ACeD | Celiac Disease

About Celiac Disease (CeD)

  1. Celiac Disease (CeD) is a serious autoimmune disease.
  2. Ingestion of gluten in genetically predisposed people leads to damage in the small intestine.
  3. There are currently no approved therapeutic treatments for CeD.

What is the ACeD Study?

Assessment of KAN-101 in Celiac Disease

The ACeD trial evaluated a potential treatment for Celiac Disease (CeD) in a phase 1 clinical study in volunteers with CeD.

The trial enrolled individuals:

  • ❯ 18-70 years old
  • ❯ Diagnosed with Celiac Disease (CeD)
  • ❯ Gluten free diet for more than 1 year

If you’re interested in further details about this completed trial, including the results, please reference the ACeD Trial.
Additional information on a newly initiated Phase 1b/2 clinical trial for some individuals with celiac disease is available at KAN-101-02 Ph1b/2 Clinical Trial.

What is KAN-101?

KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease. We deliver the antigen to the liver and immune system with our liver targeting glycosylation signature.

About Clinical Research

What is clinical research?

Clinical research is the process of developing medicines or therapies to possibly prevent, treat, or help with diseases. Before a medicine can become widely available, it must be tested in a series of clinical trials (sometimes called clinical studies) to understand its safety and effectiveness.

Your safety is the top priority of any clinical trial

Study investigators closely monitor the health of everyone who volunteers for clinical trials and receives study medications. If your health gets significantly worse, your study team will decide the best way to protect your health. This might include leaving the study early.

The phases of clinical research

There are usually three phases of clinical trials that investigational medications must go through before regulatory authorities can consider approving them for wider use. These phases study different aspects about the investigational medications and look at it in different groups of people.

Phase 1

  • Is the investigational medication safe?

❯ A small group of volunteers with the disease or healthy volunteers

Phase 2

  • Is the investigational medication safe?
  • Is it effective?
  • How does it work in the body?

❯ A group of volunteers with the disease

Phase 3

  • Confirm the investigational medication is safe
  • Confirm it is effective

❯ A larger group of volunteers with the disease

KAN-101 is in Phase 1

Taking part is voluntary

You do not need to take part in any clinical trial if you don’t want to. Even if you qualify and decide to join, you are free to leave at any time. Just let your study team know so they can do a final health check.

Taking part is at no cost to you

The study medication and all trial-related tests and procedures not considered part of your usual care are normally provided at no cost. If you live in the US, you don’t need insurance to participate. In some locations, transportation to and from study visits or reimbursement for travel-related costs may also be provided, so be sure to ask your study team.

For more information about living with Celiac Disease, please visit:


We are ensuring that our clinical sites are adhering to national, state, local, and clinical site guidelines during the ongoing COVID-19 pandemic.